Which are the most active behavioral-health VCs in 2026?

General Catalyst Health Assurance, Andreessen Horowitz Bio + Health, GV, 7wireVentures, Optum Ventures, Oak HC/FT, Define Ventures, .406 Ventures, Frist Cressey Ventures, and Flare Capital lead the sector. Payer strategics include CVS Health Ventures, Humana, Blue Venture Fund, Cigna Ventures, Elevance Health / Anthem, UPMC Enterprises, and Kaiser Permanente Ventures.

Do I need signed payer contracts to raise a Series A?

Effectively yes as of 2026. Vague 'payer partnerships' language does not close rounds. Investors ask for contract counterparty by name, member lives covered, effective date, and rate schedule.

What clinical outcomes do investors want to see?

PHQ-9 (depression) and GAD-7 (anxiety) improvement, retention curves, no-show rate, and time-to-first-appointment. Peer-reviewed publication (JAMA Network Open, JMIR) or an RCT meaningfully strengthens the case.

Is digital therapeutics still fundable after Pear Therapeutics?

Yes but with a much higher bar. FDA clearance without a secured reimbursement pathway is not a business — Pear proved that. Investors now require concrete CPT / HCPCS coding strategy and paying commercial or Medicare/Medicaid lives before Series B.

What about psychedelics fundraising after the 2024 MDMA CRL?

The FDA's 2024 Complete Response Letter for Lykos' MDMA-assisted therapy reset expectations. Fundable strategies focus on ketamine clinics (existing DEA pathway), post-approval commercialization infrastructure, and drug-development platforms with 2–3 shots on goal rather than single-asset bets.

Mental Health Fundraising: Active VCs & Payer Playbook

How to raise venture capital for a mental health or behavioral health startup in 2026.

How to Raise Venture Capital for a Mental Health Startup

Mental and behavioral health — Spring Health, Lyra, Headway, Rula (formerly Path/Bicycle Health), Grow Therapy, Alma, Talkspace, BetterHelp, and psychedelics (Compass Pathways, atai) — has a distinct payer landscape, clinical evidence bar, and regulatory posture (FDA for DTx, DEA for controlled substances).

Why mental health is a distinct fundraising category

Behavioral health rounds are underwritten on payer contract velocity, clinician supply economics, clinical outcomes (PHQ-9, GAD-7 improvement), and CPT-code reimbursement stability. Post-2022 correction cut valuations 40–60% — investors now expect margin discipline over pure growth.

The most active behavioral-health VCs

Health-focused funds active in behavioral health: General Catalyst (Health Assurance), Andreessen Horowitz Bio + Health, GV, 7wireVentures, Optum Ventures, Oak HC/FT, Define Ventures, .406 Ventures, Frist Cressey Ventures, and Flare Capital.

Multi-stage generalists active in behavioral health: Sequoia, Kleiner Perkins, Tiger Global, Coatue, Founders Fund, Lightspeed, and Insight Partners.

Strategic capital: CVS Health Ventures, Humana, Blue Venture Fund (Blues plans), Cigna Ventures, Elevance Health / Anthem, UPMC Enterprises, and Kaiser Permanente Ventures.

Psychedelics-specific: PsyMed Ventures, Iter Investments, Palo Santo, and Conscious Fund.

Payer contracting realities

In-network contracting with UnitedHealthcare/Optum, Elevance/Anthem, Cigna/Evernorth, Aetna/CVS, Humana, and regional Blues plans is the growth engine — and the bottleneck. 12–24 month contracting cycles are normal.

Investors ask for signed payer contracts by name, member lives covered, effective dates, and rate schedules. Vague 'payer partnerships' language does not close rounds anymore.

Value-based / risk-bearing contracts (Spring Health, Lyra playbook) are the premium multiple — but require actuarial capability, care management infrastructure, and 24-month cohort outcomes data.

Clinical outcomes evidence

PHQ-9 (depression) and GAD-7 (anxiety) improvement, retention, no-show rates, and time-to-first-appointment are baseline. Peer-reviewed publication (JAMA Network Open, JMIR) or an RCT strengthens the payer and investor case. Digital therapeutics (Pear Therapeutics' bankruptcy lessons) require FDA clearance plus payer reimbursement — one without the other is not a business.

Common mistakes when raising for behavioral health

Overstating clinician supply. Naming payer 'partnerships' without signed in-network contracts. Missing PHQ-9 / GAD-7 outcome data. Underestimating no-show rates. Building a DTx without securing reimbursement pathway. Skipping DEA registration for controlled-substance workflows.

Frequently asked questions

Which are the most active behavioral-health VCs in 2026?: General Catalyst Health Assurance, Andreessen Horowitz Bio + Health, GV, 7wireVentures, Optum Ventures, Oak HC/FT, Define Ventures, .406 Ventures, Frist Cressey Ventures, and Flare Capital lead the sector. Payer strategics include CVS Health Ventures, Humana, Blue Venture Fund, Cigna Ventures, Elevance Health / Anthem, UPMC Enterprises, and Kaiser Permanente Ventures.
Do I need signed payer contracts to raise a Series A?: Effectively yes as of 2026. Vague 'payer partnerships' language does not close rounds. Investors ask for contract counterparty by name, member lives covered, effective date, and rate schedule.
What clinical outcomes do investors want to see?: PHQ-9 (depression) and GAD-7 (anxiety) improvement, retention curves, no-show rate, and time-to-first-appointment. Peer-reviewed publication (JAMA Network Open, JMIR) or an RCT meaningfully strengthens the case.
Is digital therapeutics still fundable after Pear Therapeutics?: Yes but with a much higher bar. FDA clearance without a secured reimbursement pathway is not a business — Pear proved that. Investors now require concrete CPT / HCPCS coding strategy and paying commercial or Medicare/Medicaid lives before Series B.
What about psychedelics fundraising after the 2024 MDMA CRL?: The FDA's 2024 Complete Response Letter for Lykos' MDMA-assisted therapy reset expectations. Fundable strategies focus on ketamine clinics (existing DEA pathway), post-approval commercialization infrastructure, and drug-development platforms with 2–3 shots on goal rather than single-asset bets.

Related fundraising verticals (40)

Investor directory · Fundraising library · Articles A–Z · Company funding database